PT Kalbe Farma Tbk

As of June 30, 2026, PT Kalbe Farma Tbk carries a market capitalization of 34.62T, placing it among publicly traded companies globally. Its enterprise value stands at 31.89T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

PT Kalbe Farma Tbk's next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, PT Kalbe Farma Tbk has 45.25B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, PT Kalbe Farma Tbk maintains a current ratio of 3.15, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Inventory turnover of 3.16 indicates how many times PT Kalbe Farma Tbk sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, PT Kalbe Farma Tbk recorded 813.66B in income tax expense.

As of the close on October 23, 2026, PT Kalbe Farma Tbk's stock has declined approximately 39.24% over the past 52 weeks. The 50-day moving average sits at 759.10, while the 200-day moving average is 889.65.

These figures cover the twelve months ended June 30, 2026.

As of June 30, 2026, PT Kalbe Farma Tbk holds 4.99T in cash and equivalents against 825.35B in total debt, resulting in a net debt position of -4.05T. Total book value stands at 24.33T, with working capital of 14.33T providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

PT Kalbe Farma Tbk's most recent stock split took place on October 8, 2012 with a 1:5 split ratio.